[go: up one dir, main page]

UY28251A1 - USE OF THE HYDROCHLORIDE OF THE BASIS OF THE ACTIVE PRINCIPLE 1- (N2- (3,5-DIBROMO-N - ((4- (3,4-DIHIDRO-2 (1H) - OXOQUINAZOLIN-3-IL) -1-PIPERIDINIL) -CARBONIL) -D-TIROSIL) -L-LISIL) -4- (4-PIPPERIDIN) -PIPERAZINE IN COMBINATION WITH SUMATRIPTANE FOR THE TREATMENT OF - Google Patents

USE OF THE HYDROCHLORIDE OF THE BASIS OF THE ACTIVE PRINCIPLE 1- (N2- (3,5-DIBROMO-N - ((4- (3,4-DIHIDRO-2 (1H) - OXOQUINAZOLIN-3-IL) -1-PIPERIDINIL) -CARBONIL) -D-TIROSIL) -L-LISIL) -4- (4-PIPPERIDIN) -PIPERAZINE IN COMBINATION WITH SUMATRIPTANE FOR THE TREATMENT OF

Info

Publication number
UY28251A1
UY28251A1 UY28251A UY28251A UY28251A1 UY 28251 A1 UY28251 A1 UY 28251A1 UY 28251 A UY28251 A UY 28251A UY 28251 A UY28251 A UY 28251A UY 28251 A1 UY28251 A1 UY 28251A1
Authority
UY
Uruguay
Prior art keywords
dibromo
piperazine
hydrochloride
treatment
active principle
Prior art date
Application number
UY28251A
Other languages
Spanish (es)
Inventor
Klaus Rudolf
Henri Doods
Wolfgang Eberlein
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY28251A1 publication Critical patent/UY28251A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un procedimiento para el tratamiento o la prevención de dolores de cabeza, migrana o cefalea acumulada, en el que el procedimiento comprende la administración común de una cantidad terapéuticamente eficaz del hidrocloruro de la base del principio activo 1-(N2-(3,5-dibromo-N-((4-(3,4-dihidro-2(1H)-oxo-quinazolin-3 - il)-1-piperidinil)-carbonil)-D-tirosil)- L - lisil) -4- (4-piperidin) -piperazina (A) y una cantidad terapéuticamente eficaz del principio activo contra la migrana sumatriptano, o una de las sales fisiológicamente aceptables del mismo, así como la correspondiente composición farmacéutica y su producción.The present invention relates to a method for the treatment or prevention of headaches, migraine or cumulative headache, in which the method comprises the common administration of a therapeutically effective amount of the hydrochloride of the base of the active principle 1- (N2 - (3,5-dibromo-N - ((4- (3,4-dihydro-2 (1H) -oxo-quinazolin-3-yl) -1-piperidinyl) -carbonyl) -D-tyrosyl) - L - lysyl) -4- (4-piperidin) -piperazine (A) and a therapeutically effective amount of the active ingredient against migraine sumatriptan, or one of the physiologically acceptable salts thereof, as well as the corresponding pharmaceutical composition and its production.

UY28251A 2003-04-01 2004-03-31 USE OF THE HYDROCHLORIDE OF THE BASIS OF THE ACTIVE PRINCIPLE 1- (N2- (3,5-DIBROMO-N - ((4- (3,4-DIHIDRO-2 (1H) - OXOQUINAZOLIN-3-IL) -1-PIPERIDINIL) -CARBONIL) -D-TIROSIL) -L-LISIL) -4- (4-PIPPERIDIN) -PIPERAZINE IN COMBINATION WITH SUMATRIPTANE FOR THE TREATMENT OF UY28251A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10314617A DE10314617A1 (en) 2003-04-01 2003-04-01 Use of the hydrochloride of the active ingredient base 1- [N2- [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] - D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine in combination with sumatriptan for the treatment of migraines

Publications (1)

Publication Number Publication Date
UY28251A1 true UY28251A1 (en) 2004-11-08

Family

ID=32980861

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28251A UY28251A1 (en) 2003-04-01 2004-03-31 USE OF THE HYDROCHLORIDE OF THE BASIS OF THE ACTIVE PRINCIPLE 1- (N2- (3,5-DIBROMO-N - ((4- (3,4-DIHIDRO-2 (1H) - OXOQUINAZOLIN-3-IL) -1-PIPERIDINIL) -CARBONIL) -D-TIROSIL) -L-LISIL) -4- (4-PIPPERIDIN) -PIPERAZINE IN COMBINATION WITH SUMATRIPTANE FOR THE TREATMENT OF

Country Status (9)

Country Link
EP (1) EP1631282A1 (en)
JP (1) JP2006522044A (en)
AR (1) AR043793A1 (en)
CA (1) CA2520930A1 (en)
CL (1) CL2004000686A1 (en)
DE (1) DE10314617A1 (en)
TW (1) TW200501956A (en)
UY (1) UY28251A1 (en)
WO (1) WO2004087134A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563687A1 (en) * 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
WO2010046399A1 (en) * 2008-10-22 2010-04-29 Novartis Ag Combinations for the treatment of migraine
US9918932B2 (en) 2016-02-19 2018-03-20 Zosano Pharma Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines
US11660264B2 (en) 2017-08-23 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
US11660265B2 (en) 2018-06-28 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139410A1 (en) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Use of BIBN4096 in combination with other anti-migraine drugs for the treatment of migraines
DE10206770A1 (en) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma New, stable acid addition salts of the quinazolinone derivative CGRP antagonist BIBN4096, useful for the treatment of migraine, in the form of an inhalable powder

Also Published As

Publication number Publication date
DE10314617A1 (en) 2004-10-14
AR043793A1 (en) 2005-08-10
CA2520930A1 (en) 2004-10-14
JP2006522044A (en) 2006-09-28
TW200501956A (en) 2005-01-16
EP1631282A1 (en) 2006-03-08
CL2004000686A1 (en) 2005-02-04
WO2004087134A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
MXPA05012573A (en) Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors.
NO20080164L (en) N- (pyridin-2-yl) -sulfonamidderivater
ATE468332T1 (en) PHENYL-(4-(3-PHENYL-1H-PYRAZOLE-4-YL)-PYRIMIDINE- - YI)AMINE DERIVATIVES
UY27416A1 (en) USE OF BIBN4096 IN COMBINATION WITH OTHER ANTIMIGRANOSE DRUGS FOR THE TREATMENT OF MIGRANA
ES2376043T3 (en) INDAZOL DERIVATIVES FOR THE TREATMENT OF DISEASES INDUCED BY HSP90.
NO20082088L (en) Acetidines as MEK inhibitors for the treatment of proliferative diseases
NO20080827L (en) Solid dosage formulations of narcotic drugs that have improved buccal adsorption
UY27755A1 (en) NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS.
UY30316A1 (en) SUBSTITUTED DERIVATIVES OF BENZAMIDS, NICOTINAMIDS, PROPANAMIDS, ACETAMIDS AND CARBOXAMIDS N- (2- (PIPERIDIN-1-ILMETIL) CICLOHEXIL) REPLACED, PREPARATION PROCESSES, COMPOSITIONS CONTAINING AND APPLICATIONS
HN2004000232A (en) "PIRROLO DERIVATIVES (3,4-C) PIRAZOL ACTIVE AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM."
NO20071137L (en) New piperidine derivatives for the treatment of depression
SE0401342D0 (en) Therapeutic compounds
PE20211818A1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INCLUDING A DERIVATIVE OF AMINOPYRIMIDINE OR ITS SALT
AR063538A1 (en) TREATMENT OF PARKINSON'S DISEASE
UY28536A1 (en) DERIVATIVES OF BENCIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATION AND USES OF THE SAME.
ECSP066327A (en) COMPOSITION OF FEXOFENADINE AND PROCESS TO PREPARE IT
DOP2005000039A (en) HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
BRPI0411324A (en) pharmaceutical compositions and methods of treating histamine-mediated response in patients
CY1112718T1 (en) N- (2-Hydroxyethyl) -N-Methyl-4- (quinolin-8-yl (1- (thiazole-4-ylmethyl) piperidin-4-ylideno) methyl) benzamide THE THERAPEUTIC TREATMENT OF PAIN, ANXIETY AND DEPRESSION
GT200500020A (en) DERIVATIVES OF 1H-TIENO [2,3-C] PIRAZOL USEFUL AS QUINASE INHIBITORS.
UY28251A1 (en) USE OF THE HYDROCHLORIDE OF THE BASIS OF THE ACTIVE PRINCIPLE 1- (N2- (3,5-DIBROMO-N - ((4- (3,4-DIHIDRO-2 (1H) - OXOQUINAZOLIN-3-IL) -1-PIPERIDINIL) -CARBONIL) -D-TIROSIL) -L-LISIL) -4- (4-PIPPERIDIN) -PIPERAZINE IN COMBINATION WITH SUMATRIPTANE FOR THE TREATMENT OF
MA32628B1 (en) Antifungal agents
ES2197781A1 (en) Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen
AR058047A1 (en) ADMINISTRATION OF DIPEPTIDIL PEPTIDASA INHIBITORS
PE20030277A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING 2- [5- (4-FLUOROPHENIL) -3-PYRIDYLMETHYLAMINOMETHYL] -CHROMANE AND L-DOPA

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150521